Business Context and Reporting Period
Company: Coherus BioSciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 9, 2017 (Event Date)
Reporting Period: Specific events occurring on June 9, 2017, and reported on June 12, 2017.
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Events
- Regulatory Update (CHS-1701): On June 9, 2017, the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its biologics license application for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate.
- Intellectual Property Victory: On June 9, 2017, the Patent Trial and Appeal Board (PTAB) ruled in favor of the Company's petitions for Inter Partes Review. The decision invalidated all claims of AbbVie's U.S. Patents 9,017,680 and 9,073,987 related to a method for treating rheumatoid arthritis by administering 40 mg of HUMIRA® subcutaneously every 13 to 15 days.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release dated June 12, 2017, detailing the FDA CRL and the PTAB ruling. No specific financial guidance or forward-looking outlook is provided within this document.
Risks and Contingencies:
- The receipt of a Complete Response Letter indicates that the FDA has not approved the CHS-1701 application in its current form, which may delay market entry or require additional data.
- The PTAB ruling removes specific patent barriers related to AbbVie's HUMIRA® dosing method, potentially mitigating litigation risks associated with these specific patents.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific details regarding the FDA's reasons for the Complete Response Letter on CHS-1701.
- Verify the scope of the invalidated AbbVie patents to understand the impact on the Company's potential biosimilar launch strategy for HUMIRA®.
- Monitor subsequent filings for any updated timelines regarding the resubmission of the CHS-1701 application.